FibroGen FGEN 深 滬
等待開盤 12-12 09:30:00 美东时间
8.70
-0.120
-1.36%
華盛通- 最 高9.0883
- 今 開8.77
- 成交量 1.22万股
- 最 低 8.70
- 昨 收 8.82
- 總市值 3518.19万
- 52周最高 21.9375
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 4.85
- 委 比 -94.00%
- 總股本 404.39万
- 歷史最高 1713.75
- 量 比 0.65
- 振 幅 4.40%
- 歷史最低 4.50
- 每 手 1
- 風險率 2.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
FibroGen, Inc. announced it will attend and present at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, in New York, NY. Thane Wettig, CEO of FibroGen, will participate in a panel titled "Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts" at 12:15 PM ET. The company's management team will also be available for one-on-one meetings. FibroGen is focused on developing novel therapie...
12-02 21:05
FibroGen Q3 EPS continuing operations $(3.50) Beats $(4.00) Estimate, Sales $1.076M Miss $1.640M Estimate
FibroGen (NASDAQ:FGEN) reported quarterly losses of $(3.50) per share which beat the analyst consensus estimate of $(4.00) by 12.61 percent. This is a 17.65 percent increase over losses of $(4.25) per share from the same
11-11 05:04
FibroGen Receives $6.4 Million Payment from AstraZeneca
FibroGen ( ($FGEN) ) has provided an announcement. On November 6, 2025, FibroGe...
11-07 05:38
FibroGen to Report Third Quarter 2025 Financial Results
FibroGen, Inc. will announce its third quarter 2025 financial results on November 10 after market close. A conference call and webcast presentation will follow at 5:00 PM Eastern Time, featuring FibroGen's management team discussing the financial results and providing a business update. Interested parties can access the live webcast or register for the call via the links provided. FibroGen, a biopharmaceutical company, focuses on developing novel...
11-03 21:02
FG Nexus Announces Acceptance of Historic 1 Trillion Share Authorization by the State of Nevada
FG Nexus announced on October 7, 2025, that its amendment to its articles of incorporation has been effective, authorizing up to 1 trillion shares, including 900 billion common shares and 100 billion preferred shares. This change, approved by shareholders, aims to enhance flexibility for increased ETH per share and long-term shareholder value. The company focuses on becoming the world's largest ETH holder through staking and yield strategies.
10-08 11:30
FG Nexus and Securitize Enter into Agreement to Natively Tokenize FG Nexus Public Shares on Ethereum
FG Nexus and Securitize have teamed up to tokenize FG Nexus's common and preferred shares on Ethereum, making it the first NASDAQ-listed company to offer native blockchain equity with the same rights as traditional shares. This breakthrough brings programmable ownership, real-time settlement, and enhanced investor access while maintaining regulatory compliance. The initiative underscores FG Nexus's commitment to financial innovation and aligns wi...
10-02 12:00
美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
09-25 09:52
FibroGen Begins Phase 2 Trial Of New Prostate Cancer Drug FG-3246 With UCSF As First Site
FibroGen, Inc. (NASDAQ:FGEN) today announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46-expressing cancer
09-24 19:03
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
FibroGen has initiated a Phase 2 dose optimization trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial will enroll 75 patients and also assess FG-3180, a companion PET imaging agent, as a diagnostic and predictive biomarker. An interim analysis is expected in the second half of 2026. FG-3246 has shown promising clinical activi...
09-24 11:00
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million
FibroGen announced the successful sale of its China subsidiary to AstraZeneca for approximately $220 million, an increase of $60 million from initial guidance. The transaction includes $85 million in enterprise value and $135 million in net cash. FibroGen also repaid a $81 million term loan to Morgan Stanley Tactical Value, simplifying its capital structure. The sale extends the company's cash runway into 2028. FibroGen plans to initiate a Phase ...
09-02 11:00
